Medication info
Ezatine Tablet (Memantine Hydrochloride)

Ezatine Tablet (Memantine Hydrochloride)

Prescription medicationTabletOral
Ingredient · strength
Memantine Hydrochloride›10mg / 1 tablet
Manufacturer / importer
Alboyzen Korea Co., Ltd.
Appearance
Pale yellow to yellow oval film-coated tablets
Packaging
30 tablets/bottle, 100 tablets/bottle
Approval status
Active

MFDS item code 201405063 · Approved 2014.10.30 · Insurance code 652604780

Summary

Main use
Treatment of moderate to severe Alzheimer's disease
Who takes it
Adults
Adult dose
This medicine is administered orally once daily, at the same time each day. If necessary, this medicine may be administered twice daily. This medicine may be taken with or without food. 1. Adults Dose titration: The maximum daily dose is 20mg. To minimize the risk of adverse reactions, increase the dose by 5mg per week over the first 3 weeks as follows to reach the maintenance dose. Week 1 (days 1–7): Administer 5mg daily for 7 days. Week 2 (days 8–14): Administer 10mg daily for 7 days. Week 3 (days 15–21): Administer 15mg daily for 7 days. From week 4 onward: Administer 20mg daily. Maintenance dose: The recommended maintenance dose is 20mg daily. 2. Older adults: Based on clinical data, the recommended dose for older patients aged 65 years or older is 20mg daily. 3. Patients with renal impairment: No dose adjustment is necessary in patients with mild renal impairment (creatinine clearance: 50-80 mL/min). In patients with moderate renal impairment (creatinine clearance 30-49 mL/min), reduce the daily dose to 10mg. If well tolerated, the dose may be increased to 20mg daily in accordance with the standard dose-titration regimen after at least 7 days of treatment. In patients with severe renal impairment (creatinine clearance 5-29 mL/min), reduce the daily dose to 10mg. 4. Patients with hepatic impairment: No dose adjustment is necessary in patients with mild or moderate hepatic impairment (Child-Pugh A, Child-Pugh B). There are no data on the use of memantine in patients with severe hepatic impairment; therefore, it is preferable not to administer this medicine.

Ingredients

Manufacturer
Alboyzen Korea Co., Ltd.

Efficacy & effects

Treatment of moderate to severe Alzheimer's disease

  • Alzheimer's disease
View approved original text

This medication is used for the treatment of moderate to severe Alzheimer's disease.

How to take

Adult dose

This medicine is administered orally once daily, at the same time each day. If necessary, this medicine may be administered twice daily. This medicine may be taken with or without food. 1. Adults Dose titration: The maximum daily dose is 20mg. To minimize the risk of adverse reactions, increase the dose by 5mg per week over the first 3 weeks as follows to reach the maintenance dose. Week 1 (days 1–7): Administer 5mg daily for 7 days. Week 2 (days 8–14): Administer 10mg daily for 7 days. Week 3 (days 15–21): Administer 15mg daily for 7 days. From week 4 onward: Administer 20mg daily. Maintenance dose: The recommended maintenance dose is 20mg daily. 2. Older adults: Based on clinical data, the recommended dose for older patients aged 65 years or older is 20mg daily. 3. Patients with renal impairment: No dose adjustment is necessary in patients with mild renal impairment (creatinine clearance: 50-80 mL/min). In patients with moderate renal impairment (creatinine clearance 30-49 mL/min), reduce the daily dose to 10mg. If well tolerated, the dose may be increased to 20mg daily in accordance with the standard dose-titration regimen after at least 7 days of treatment. In patients with severe renal impairment (creatinine clearance 5-29 mL/min), reduce the daily dose to 10mg. 4. Patients with hepatic impairment: No dose adjustment is necessary in patients with mild or moderate hepatic impairment (Child-Pugh A, Child-Pugh B). There are no data on the use of memantine in patients with severe hepatic impairment; therefore, it is preferable not to administer this medicine.

Precautions

This medication should not be used in patients who are allergic to any of its ingredients. It is also advisable not to administer it to patients with very poor liver function or severely impaired kidney function. Patients with epilepsy or a history of seizures should use this medication cautiously, and it is recommended not to combine it with certain other medications as it may increase the risk of side effects. Additionally, patients with altered urine acidity or heart diseases should be monitored carefully. During treatment with this medication, symptoms such as dizziness, headache, constipation, drowsiness, and hypertension may occur, and hallucinations or psychiatric symptoms have been reported rarely. If these symptoms are severe, it is important to consult medical personnel immediately. There may be interactions with other medications; therefore, particularly if taking NMDA antagonists, antipsychotic drugs, muscle relaxants, or anticoagulants, patients should inform their doctors or pharmacists and proceed with caution. Women who are pregnant or may become pregnant should consult a doctor before taking this medication, and it is recommended to discontinue breastfeeding while using this medication. The safety and efficacy of this medication have not been established in children and adolescents under the age of 18, so it is advisable not to use it in these populations. In the event of overdose, central nervous system symptoms or gastrointestinal symptoms may appear, and if suspected, it is vital to visit a hospital immediately for appropriate treatment. Lastly, this medication may affect the patient's reaction time, so caution should be taken when driving or operating machinery. Special care should be taken when engaging in these activities. Finally, this medication should be stored out of reach of children and care should be taken not to transfer it to another container.

Side effects

  • Dizziness
  • headache
  • constipation
  • drowsiness
  • hypertension
  • fungal infection
  • drug hypersensitivity
  • confusion
  • hallucinations
  • psychotic reactions
Show 19 more
  • balance disorder
  • gait abnormalities
  • seizures
  • heart failure
  • venous thrombosis/thromboembolism
  • dyspnea
  • vomiting
  • pancreatitis
  • elevated liver function test results
  • hepatitis
  • fatigue
  • abnormal stupor
  • double vision
  • anxiety
  • psychosis
  • visual hallucinations
  • delirium
  • unconsciousness
  • restlessness

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly closed container to prevent exposure to air or moisture. The recommended storage temperature is room temperature between 1 to 30 degrees Celsius.

Appearance and packaging

Appearance

Pale yellow to yellow oval film-coated tablets

Package unit

30 tablets/bottle, 100 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.